Back to results
US 4,925,922 AGranted
Potentiation of cytotoxic conjugates
AssigneeXoma Corporation
InventorsVera S. Byers, Robert W. Baldwin, Patrick J. Scannon
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeXoma Corporation
InventorsVera S. Byers, Robert W. Baldwin, Patrick J. Scannon
Estimating the term…
Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. For some of these compositions, an enhanced or potentiated efficacy is observed when the conjugates are administered along with a related, unconjugated monoclonal antibody. Hybridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively. Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.
A method for potentiating the cytotoxicity of a cytotoxic immunoconjugate, said method comprising administering said immunoconjugate including a ribosomal inhibiting toxin bound to a first immunoglobulin which binds specifically to a first epitope of a tumor cell surface antigen and a potentiating amount of a second immunoglobulin which binds specifically to a second distinct epitope on said cell surface antigen, wherein said potentiating effect derives from the binding of said second immunoglobulin to said second distinct epitope.
Dependencies are inferred from the claim text.